1. Home
  2. CHCT vs PRTA Comparison

CHCT vs PRTA Comparison

Compare CHCT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Healthcare Trust Incorporated

CHCT

Community Healthcare Trust Incorporated

HOLD

Current Price

$17.56

Market Cap

501.7M

Sector

Real Estate

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.08

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCT
PRTA
Founded
2014
2012
Country
United States
Ireland
Employees
35
67
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
501.7M
526.7M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
CHCT
PRTA
Price
$17.56
$10.08
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$18.00
$19.00
AVG Volume (30 Days)
172.9K
477.6K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
11.07%
N/A
EPS Growth
134.78
N/A
EPS
0.07
0.60
Revenue
$121,195,000.00
$814,000.00
Revenue This Year
$9.06
$1,111.38
Revenue Next Year
$8.61
N/A
P/E Ratio
$250.71
$16.52
Revenue Growth
4.67
N/A
52 Week Low
$13.23
$4.42
52 Week High
$18.22
$11.80

Technical Indicators

Market Signals
Indicator
CHCT
PRTA
Relative Strength Index (RSI) 55.62 50.13
Support Level $16.45 $9.43
Resistance Level $18.17 $10.11
Average True Range (ATR) 0.37 0.63
MACD 0.01 -0.02
Stochastic Oscillator 73.55 37.05

Price Performance

Historical Comparison
CHCT
PRTA

About CHCT Community Healthcare Trust Incorporated

Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: